Prévisions
L'objectif de cours moyen des analystes est de 4,56 € (+178,05 %). La médiane est de 4,56 € (+178,05 %).
| Acheter |
4 |
| Conserver |
0 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Eledon applies to FDA for Tegoprubart indication in islet cell transplantation
Eledon has filed an investigational new drug (IND) application with the FDA for a registration‑enabling study of the anti‑CD40L antibody Tegoprubart for immunosuppression in islet cell transplants for type 1 diabetes. The study would be Eledon’s first company‑sponsored trial in this area; investigator‑initiated studies are already underway at UChicago, Duke and MGH, and compassionate‑use treatments are also being provided. Earlier results in 12 treated patients showed insulin independence, HbA1c <7.0% and stable graft function for up to 22 months; Eledon also plans to start the global phase‑3 LEGACY study in kidney transplantation in Q4 2026 with about 600 patients. » Plus sur de.investing.com
Eledon Pharmaceuticals presents phase‑2 results and plans phase‑3 alignment with FDA
At the Leerink conference, Eledon Pharmaceuticals presented data on tegoprubart in kidney transplants, showing non‑inferiority to tacrolimus and a better safety profile, but no statistically significant superiority in kidney function. The company plans to finalize the phase‑3 study design with the FDA by year‑end and aims to start the trial within the year. Eledon received orphan‑drug designation for liver transplantation, is planning a liver‑related investigator‑sponsored trial (IST), and is evaluating expansion and strategic partnerships in islet‑cell transplantation. Cash on hand exceeds $130 million, providing a runway into the second quarter of next year. » Plus sur de.investing.com
Eledon Pharmaceuticals plans phase‑3 for Tegoprubart despite missed endpoints
At the Guggenheim Summit Eledon Pharmaceuticals said Tegoprubart showed significant safety advantages in kidney transplant studies, but the phase‑2 BESTOW trial missed its primary endpoint for renal function. The company plans to start a registrational phase‑3 trial with a composite endpoint by the end of 2026 and intends to place greater emphasis on patient‑reported outcomes. Positive early results in islet‑cell transplantation are to be advanced into a sponsored study in 2026, with an IND filing planned by year‑end. Eledon has funding into the second quarter of 2027 and is also pursuing global collaborations in xenotransplantation. » Plus sur de.investing.com
Eledon: 24-month data on tegoprubart show improved kidney function and no rejections
Eledon presented 24-month follow-up data from eight patients in the phase‑1b study of tegoprubart in kidney transplantation. Mean eGFR increased from 67.0 ml/min/1.73 m² at 12 months to 74.2 ml/min/1.73 m² at 24 months; there were no biopsy‑confirmed acute rejection episodes, graft losses, deaths, new-onset diabetes, or donor-specific antibodies reported. Tegoprubart is an anti‑CD40L antibody being investigated as a non‑lymphocyte‑depleting immunomodulatory therapy. Financials show a solid balance sheet with a high current ratio and more cash than debt, providing runway for the clinical programs. » Plus sur de.investing.com
Eledon Pharmaceuticals stock rises after positive Tegoprubart data on islet cell transplantation
Eledon Pharmaceuticals’ stock climbed about 3.3% in after-hours trading following preliminary study results for Tegoprubart in type 1 diabetes. In the ongoing University of Chicago Medicine trial, all six initial patients achieved insulin independence after one or two islet cell transplants, some for more than a year, accompanied by low HbA1c levels. Tegoprubart was well tolerated with no serious infections, thromboembolic events, rejection, or signs of kidney or neurological toxicity. The study has been expanded to 12 participants and is funded by Breakthrough T1D, which also plans to support a second study in patients with chronic kidney disease. » Plus sur de.investing.com
Données financières
Au dernier trimestre, Eledon Pharmaceuticals a réalisé un chiffre d'affaires de 0 € et un bénéfice net de -3,47 M €
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 0 | - |
| Bénéfice brut | 0 | - |
| Bénéfice net | -3,47 M | 76,66 % |
| EBITDA | -3,47 M | 76,66 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 146,25 M € |
Nombre d'actions | 84,46 M |
Plus haut/bas sur 52 semaines | 4,09 € - 1,23 € |
| Dividendes | Non |
Bêta | 0,85 |
Ratio P/E | -2,41 |
Ratio PEG | 0,17 |
Ratio P/B | 3,12 |
Ratio P/S | 0,00 |
Profil de l'entreprise
Eledon Pharmaceuticals, Inc., entreprise biopharmaceutique au stade clinique, se consacre au développement de médicaments destinés aux patients atteints de maladies auto-immunes et de sclérose latérale amyotrophique (SLA), et nécessitant une greffe d'organe ou de cellules. Son candidat-médicament principal, l'AT-1501, est un anticorps monoclonal humanisé ciblant le CD40 Ligand, une molécule exprimée à la surface des lymphocytes T du système immunitaire humain. Il est en essais cliniques de phase 2a pour le traitement de la SLA, et en essais cliniques de phase 2 en transplantation d'îlots pancréatiques pour le traitement du diabète de type 1. La société était auparavant connue sous le nom de Novus Therapeutics, Inc. et a changé de nom pour devenir Eledon Pharmaceuticals, Inc. en janvier 2021. Eledon Pharmaceuticals, Inc. a son siège social à Irvine, en Californie.
| Nom | Eledon Pharmaceuticals |
| PDG | David-Alexandre C. Gros |
| Siège social | Irvine,
ca États-Unis |
| Site web | |
| Secteur | Matériaux |
| Industrie | Produits chimiques |
| Introduction en bourse | 17/09/2014 |
| Employés | 33 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | ELDN |
Frankfurt | 2TK.F |
München | 2TK.MU |
Düsseldorf | 2TK.DU |